Chugai reports vamikibart data. Chugai Pharmaceutical stock costs EUR 35.28

Published on 10/15/2026 at 10:36 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Vamikibart data covered 52 weeks in eye disease. Chugai Pharmaceutical stock costs EUR 35.28 on October 15, 2026 before results.

Pipeline events set the agenda

Vamikibart data covered 52 weeks on October 13, 2026.
Second-quarter 2026 revenue reached JPY 341.58 billion.
Chugai Pharmaceutical stock trades at EUR 35.28 at 10:32 a.m. CEST at Lang & Schwarz on October 15, 2026.
Chugai will publish third-quarter results on October 27, 2026.

Chugai Pharmaceutical, JP3519400000, Illustration mit AI erstellt.

Chugai Pharmaceutical (JP3519400000) was trading at EUR 35.28 at Lang & Schwarz on October 15, 2026, at 10:32 a.m. CEST. The latest clinical update concerned 52-week vamikibart data in uveitic macular edema, reported by Vermogenszentrum on October 13, 2026. The data keep attention on Chugai's partnered pipeline ahead of the company's next results.

Vamikibart reaches 52 weeks

The report said Roche's Phase III studies showed sustained vision gains and reduced macular swelling through 52 weeks. About two-thirds of patients who moved to as-needed dosing required no additional treatment, while most patients who needed another injection received only one, according to Vermogenszentrum.

That pipeline signal followed two September announcements. On September 28, 2026, Chugai Pharmaceutical said it would end obesity development of emugrobart and prepare a spinal muscular atrophy program. On September 29, 2026, the company granted InxMed worldwide rights to SPYK04, a RAF-MEK molecular glue for solid tumors, in return for an upfront payment and royalties, according to Chugai Pharmaceutical.

What does second-quarter revenue show?

Chugai's second-quarter 2026 revenue was JPY 341.58 billion, up from JPY 290.01 billion a year earlier, while net profit reached JPY 116.33 billion versus JPY 97.16 billion, The Globe and Mail reported on October 13, 2026. The comparison gives the pipeline news a stronger operating backdrop, although the next update will determine whether that momentum continued into the third quarter.

Results date sets the next test

Chugai's investor-relations calendar lists third-quarter results for October 27, 2026, at 5:00 p.m. JST, followed by a results conference at 6:00 p.m. JST. The dates are published on the company's investor-relations page. For investors, the key question is whether strong reported earnings can continue to support a pipeline that is producing mixed development outcomes.

EUR quote and Tokyo context

On the Tokyo Stock Exchange, Chugai was last at JPY 6,267 on October 15, 2026, at 3:30 p.m. JST. The 52-week range was JPY 5,974.00 to JPY 10,700.00, and market capitalization was JPY 10.3 trillion on the same date. The euro quotation was trading at EUR 35.28 at Lang & Schwarz on October 15, 2026, at 10:32 a.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of Chugai Pharmaceutical stock.